Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin

Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index

(2012) Massimo Breccia et al.   LEUKEMIA RESEARCH

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

(2011) H. M. Kantarjian et al.   BLOOD

Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients

(2011) Naoto Takahashi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

(2011) Hagop M Kantarjian et al.   LANCET ONCOLOGY

Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia: Approach to Patients with Treatment-Naive or Refractory Chronic-Phase Disease

(2011) C. C. Smith et al.   Hematology-American Society of Hematology Education Program

Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib

(2010) Paul W. Manley et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

(2010) H. M. Kantarjian et al.   BLOOD

Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a ‘head-to-head comparison’

(2010) Gianantonio Rosti et al.   LEUKEMIA & LYMPHOMA

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia

(2009) G. Rosti et al.   BLOOD

The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism

(2009) Massimo Breccia et al.   LEUKEMIA RESEARCH

The Master Switch: The Role of Mast Cells in Autoimmunity and Tolerance

(2008) Blayne A. Sayed et al.   Annual Review of Immunology

Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib

(2008) M. Breccia et al.   LEUKEMIA RESEARCH

Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice

(2008) C. Louvet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet

(2007) Robert Hägerkvist et al.   CLINICAL SCIENCE